Celldex Therapeutics, Inc.
CLDX
$30.40
$1.866.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -258.76M | -224.53M | -199.61M | -178.85M | -157.86M |
| Total Depreciation and Amortization | 3.38M | 3.38M | 3.35M | 3.27M | 3.18M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.37M | 28.77M | 26.27M | 21.67M | 18.51M |
| Change in Net Operating Assets | 14.06M | 12.90M | -16.20M | -17.60M | -21.60M |
| Cash from Operations | -210.95M | -179.48M | -186.19M | -171.51M | -157.78M |
| Capital Expenditure | -2.71M | -2.19M | -2.29M | -1.84M | -1.92M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 211.79M | 179.88M | 166.90M | 69.87M | -288.21M |
| Cash from Investing | 209.07M | 177.69M | 164.61M | 68.03M | -290.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.39M | 1.43M | 1.89M | 5.54M | 441.45M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.39M | 1.43M | 1.89M | 5.54M | 441.45M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 515.00K | -362.00K | -19.70M | -97.94M | -6.46M |